Algorae Pharmaceuticals Enters Licensing Agreement with Indian Manufacturer for Launch of Generic Oncology Medicines in Australia, New Zealand

MT Newswires Live

Sep 23, 2025

Algorae Pharmaceuticals (ASX:1AI) entered into an exclusive licensing deal with Indian pharmaceutical firm Sakar Healthcare to launch five generic oncology medicines into the Australian and New Zealand markets, according to a Tuesday Australian bourse filing.

It began regulatory planning for Therapeutic Goods Administration registration to allow for product commercialization.

The firm's representatives conducted an on-site inspection of Sakar's manufacturing facilities in Ahmedabad, India, and held meetings with senior management, operational leaders, and technical staff as part of its due diligence.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2569226759"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2569226759\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2569226759?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-09-23 08:18","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2569226759","market":"us","top_or_hot":-1,"title":"Algorae Pharmaceuticals Enters Licensing Agreement with Indian Manufacturer for Launch of Generic Oncology Medicines in Australia, New Zealand","media":"MT Newswires Live","content":"<html><body><p> <a href=\"https://laohu8.com/S/LVCLF\">Algorae Pharmaceuticals</a> (ASX:1AI) entered into an exclusive licensing deal with Indian pharmaceutical firm Sakar Healthcare to launch five generic oncology medicines into the Australian and <a href=\"https://laohu8.com/S/NZERF\">New Zealand</a> markets, according to a Tuesday Australian bourse filing.</p><p>It began regulatory planning for Therapeutic Goods Administration registration to allow for product commercialization.</p><p>The firm's representatives conducted an on-site inspection of Sakar's manufacturing facilities in Ahmedabad, India, and held meetings with senior management, operational leaders, and technical staff as part of its due diligence.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Algorae Pharmaceuticals Enters Licensing Agreement with Indian Manufacturer for Launch of Generic Oncology Medicines in Australia, New Zealand</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAlgorae Pharmaceuticals Enters Licensing Agreement with Indian Manufacturer for Launch of Generic Oncology Medicines in Australia, New Zealand\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2025-09-23 08:18</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> <a href=\"https://laohu8.com/S/LVCLF\">Algorae Pharmaceuticals</a> (ASX:1AI) entered into an exclusive licensing deal with Indian pharmaceutical firm Sakar Healthcare to launch five generic oncology medicines into the Australian and <a href=\"https://laohu8.com/S/NZERF\">New Zealand</a> markets, according to a Tuesday Australian bourse filing.</p><p>It began regulatory planning for Therapeutic Goods Administration registration to allow for product commercialization.</p><p>The firm's representatives conducted an on-site inspection of Sakar's manufacturing facilities in Ahmedabad, India, and held meetings with senior management, operational leaders, and technical staff as part of its due diligence.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"XJO.AU","symbol_name":"标普/澳交所 200指数","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2569226759","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2569226759","pubTimestamp":1758586726,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Algorae Pharmaceuticals (ASX:1AI) entered into an exclusive licensing deal with Indian pharmaceutical firm Sakar Healthcare to launch five generic oncology medicines into the Australian and New Zealan","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"XJO.AU":"标普/澳交所 200指数","NZ20C.NZ":"S&P/NZX 20","XKO.AU":"标普/澳交所 300指数","XAO.AU":"标普/澳交所 普通股指数","T10G.NZ":"S&P/NZX 10","1AI.AU":"ALGORAE PHARMACEUTICALS LTD","NZ50G.NZ":"S&P/NZX 50","MDCO":"麦迪逊医药","BK7067":"生物科技"},"translate_title":"Algorae Pharmaceuticals与印度制造商签订许可协议，在澳大利亚和新西兰推出仿制肿瘤药物","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"MDCO":1.5,"NZ20C.NZ":1.5,"XJO.AU":1.5,"XKO.AU":1.5,"1AI.AU":1,"XAO.AU":1.5,"T10G.NZ":1.5,"NZ50G.NZ":1.5},"content_text":"Algorae Pharmaceuticals (ASX:1AI) entered into an exclusive licensing deal with Indian pharmaceutical firm Sakar Healthcare to launch five generic oncology medicines into the Australian and New Zealand markets, according to a Tuesday Australian bourse filing.It began regulatory planning for Therapeutic Goods Administration registration to allow for product commercialization.The firm's representatives conducted an on-site inspection of Sakar's manufacturing facilities in Ahmedabad, India, and held meetings with senior management, operational leaders, and technical staff as part of its due diligence.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}